BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
15 mai 2020 07h00 HE | BeiGene, LTD.
CAMBRIDGE, Mass., and BEIJING, China, May 15, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress
14 mai 2020 09h00 HE | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, May 14, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Reports First Quarter 2020 Financial Results
11 mai 2020 16h05 HE | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, May 11, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
29 avr. 2020 17h00 HE | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, April 29, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer in China
20 avr. 2020 16h05 HE | BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis
13 avr. 2020 16h05 HE | BeiGene, LTD.
BEIJING, China, and CAMBRIDGE, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
10 avr. 2020 18h00 HE | BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., April 10, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Supply Update for ABRAXANE® in China
25 mars 2020 09h00 HE | BeiGene, LTD.
- NMPA has suspended the importation, sales and use of ABRAXANE in China supplied by Celgene Corporation, a Bristol Myers Squibb (BMS) company - As the marketing agent for ABRAXANE in China, BeiGene...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Reports Fourth Quarter and Full Year 2019 Financial Results
02 mars 2020 16h05 HE | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, March 02, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene to Present at the Cowen and Company’s 40th Annual Health Care Conference
25 févr. 2020 07h00 HE | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Feb. 25, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...